JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Interferon-γ-induced GBP1 is an inhibitor of human papillomavirus 18

  • 0Laboratory of Prenatal Diagnosis, Mindong Hospital Affiliated to Fujian Medical University, Ningde, 355099, China.
Bmc Women's Health +

|

April 15, 2024

|

April 15, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Guanylate binding protein 1 (GBP1) effectively degrades HPV18 E6, a key factor in cervical cancer. This finding reveals GBP1 as an effector of interferon gamma (IFN-γ) anti-HPV activity, offering new treatment insights for HPV18 infections.

Area Of Science

  • Immunology
  • Virology
  • Molecular Biology

Background

  • Human papillomavirus (HPV) infection is a primary cause of cervical abnormalities, with high-risk types like HPV16 and 18 linked to 90% of cervical cancers.
  • Current treatments for HPV infections, including vaccines and antivirals, exhibit limited efficacy and scope.
  • Guanylate binding protein 1 (GBP1), an interferon gamma-induced protein, plays roles in cellular processes and pathogen clearance, but its effect on HPV is unknown.

Purpose Of The Study

  • To investigate the potential inhibitory effect of Guanylate binding protein 1 (GBP1) on human papillomavirus (HPV) infection.
  • To elucidate the mechanism by which GBP1 interacts with HPV components, specifically HPV18 E6 protein.

Main Methods

  • The study involved analyzing the interaction between GBP1 and HPV18 E6 protein.
  • Investigated the degradation of HPV18 E6 by GBP1.
  • Examined the role of the ubiquitin-proteasome pathway in the interaction between E6 and GBP1.

Main Results

  • Guanylate binding protein 1 (GBP1) was found to effectively degrade the HPV18 E6 protein, potentially via its GTPase activity.
  • The HPV18 E6 protein was observed to degrade GBP1 through the ubiquitin-proteasome pathway, indicating a mechanism for viral immune evasion.
  • GBP1 acts as an effector molecule for interferon gamma (IFN-γ) in combating HPV activity.

Conclusions

  • GBP1 demonstrates anti-HPV activity by degrading HPV18 E6, highlighting its role as an IFN-γ effector.
  • The findings offer novel therapeutic strategies for managing HPV18 infections by targeting the GBP1-E6 interaction.
  • This research provides a deeper understanding of the molecular mechanisms underlying HPV pathogenesis and host defense.

Keywords: